Menu
Search
|

Menu

Close
X

TRACON Pharmaceuticals Inc TCON.OQ (NASDAQ Stock Exchange Global Market)

2.10 USD
+0.00 (+0.00%)
As of Feb 23
chart
Previous Close 2.10
Open 2.10
Volume 9,189
3m Avg Volume 20,272
Today’s High 2.12
Today’s Low 2.10
52 Week High 4.65
52 Week Low 2.00
Shares Outstanding (mil) 17.51
Market Capitalization (mil) 36.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
3
FY15
8
EPS (USD)
FY17
-0.836
FY16
-2.144
FY15
-2.185
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
3.92
8.35
Price to Book (MRQ)
vs sector
1.67
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
33.57
15.84
LT Debt to Equity (MRQ)
vs sector
24.43
12.39
Return on Investment (TTM)
vs sector
-73.95
13.63
Return on Equity (TTM)
vs sector
-95.24
15.39

EXECUTIVE LEADERSHIP

Charles Theuer
President, Chief Executive Officer, Director, Since 2006
Salary: $486,525.00
Bonus: --
Patricia Bitar
Chief Financial Officer, Since 2014
Salary: $332,160.00
Bonus: --
H. Logan
Chief Business Officer, Since 2013
Salary: $284,460.00
Bonus: --
William LaRue
Independent Director, Since 2014
Salary: --
Bonus: --
Martin Mattingly
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4350 La Jolla Village Dr Ste 800
SAN DIEGO   CA   92122-1247

Phone: +1858.5500780

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

SPONSORED STORIES